期刊文献+

AMPK-associated signaling to bridge the gap between fuel metabolism and hepatocyte viability 被引量:4

AMPK-associated signaling to bridge the gap between fuel metabolism and hepatocyte viability
在线阅读 下载PDF
导出
摘要 The adenosine monophosphate-activated protein kinase (AMPK) and p70 ribosomal S6 kinase-1 pathway may serve as a key signaling flow that regulates energy metabolism; thus, this pathway becomes an attractive target for the treatment of liver diseases that result from metabolic derangements. In addition, AMPK emerges as a kinase that controls the redox-state and mitochondrial function, whose activity may be modulated by antioxidants. A close link exists between fuel metabolism and mitochondrial biogenesis. The relationship between fuel metabolism and cell survival strongly implies the existence of a shared signaling network, by which hepatocytes respond to challenges of external stimuli. The AMPK pathway may belong to this network. A series of drugs and therapeutic candidates enable hepatocytes to protect mitochondria from radical stress and increase cell viability, which may be associated with the activation of AMPK, liver kinase B1, and other molecules or components. Consequently, the components downstream of AMPK may contribute to stabilizing mitochondrial membrane potential for hepatocyte survival. In this review, we discuss the role of the AMPK pathway in hepatic energy metabolism and hepatocyte viability. This information may help identify ways to prevent and/or treat hepatic diseases caused by the metabolic syndrome. Moreover, clinical drugs and experimental therapeutic candidates that directly or indirectly modulate the AMPK pathway in distinct manners are discussed here with particular emphasis on their effects on fuel metabolism and mitochondrial function. The adenosine monophosphate-activated protein kinase (AMPK) and p70 ribosomal S6 kinase-1 pathway may serve as a key signaling flow that regulates energy metabolism; thus, this pathway becomes an attractive target for the treatment of liver diseases that result from metabolic derangements. In addition, AMPK emerges as a kinase that controls the redox-state and mitochondrial function, whose activity may be modulated by antioxidants. A close link exists between fuel metabolism and mitochondrial biogenesis. The relationship between fuel metabolism and cell survival strongly implies the existence of a shared signaling network, by which hepatocytes respond to challenges of external stimuli. The AMPK pathway may belong to this network. A series of drugs and therapeutic candidates enable hepatocytes to protect mitochondria from radical stress and increase cell viability, which may be associated with the activation of AMPK, liver kinase B1, and other molecules or components. Consequently, the components downstream of AMPK may contribute to stabilizing mitochondrial membrane potential for hepatocyte survival. In this review, we discuss the role of the AMPK pathway in hepatic energy metabolism and hepatocyte viability. This information may help identify ways to prevent and/or treat hepatic diseases caused by the metabolic syndrome. Moreover, clinical drugs and experimental therapeutic candidates that directly or indirectly modulate the AMPK pathway in distinct manners are discussed here with particular emphasis on their effects on fuel metabolism and mitochondrial function.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2010年第30期3731-3742,共12页 世界胃肠病学杂志(英文版)
基金 Supported by The National Research Foundation of Korea Grant,Funded by the Korea Government(MEST),No.2010-0001706,South Korea
关键词 Adenosine monophosphate-activated protein KINASE Cell survival Energy METABOLISM Fatty liver Insulin resistance GLYCOGEN synthase KINASE P70 RIBOSOMAL S6 kinase-1 Adenosine monophosphate-activated protein kinase Cell survival Energy metabolism Fatty liver Insulin resistance Glycogen synthase kinase 3β p70 ribosomal S6 kinase-1
  • 相关文献

参考文献1

二级参考文献37

  • 1Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2006; 37: 635-46.
  • 2Festi D, Colec'chia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004; 5: 27-42.
  • 3Akbar DH, KawtherAH. Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don't know. Med Sci Monit 2006; 12: RA23-RA26.
  • 4ClarkJM, DiehlAM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289: 3000-4.
  • 5Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-9.
  • 6Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905.
  • 7Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 28: 2-12.
  • 8Marcaurelle LA, Johannes CW. Application of natural product-inspired diversity-oriented synthesis to drug discovery. Prog Drug Res 2008; 66: 189-216.
  • 9Lin CL, HuangHC, Lin JK. Theaflavinsattenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J Lipid Res 2007; 48: 2334-43.
  • 10Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006; 55: 2180-91.

共引文献19

同被引文献62

  • 1王宇光,杨明会,马增春,梁乾德,谭洪玲,肖成荣,高月.18β-甘草酸和18α-甘草酸对大鼠原代肝细胞CYP3A酶表达的影响[J].中国中药杂志,2009,34(3):307-311. 被引量:37
  • 2Gregorios Hatzis,Panayiotis Ziakas,Nikolaos Kavantzas,Aggeliki Triantafyllou,Panagiotis Sigalas,Ioanna Andreadou,Konstantinos Ioannidis,Stamatios Chatzis,Konstantinos Filis,Alexandros Papalampros,Fragiska Sigala.Melatonin attenuates high fat diet-induced fatty liver disease in rats[J].World Journal of Hepatology,2013,5(4):160-169. 被引量:5
  • 3陈璐璐,邓向群,李凝旭.热卡限制对非酒精性脂肪肝病大鼠肝脏SIRT1表达的影响[J].中华医学杂志,2007,87(20):1434-1437. 被引量:6
  • 4Frank Tacke,Tom Luedde,Christian Trautwein.Inflammatory Pathways in Liver Homeostasis and Liver Injury[J]. Clinical Reviews in Allergy & Immunology . 2009 (1)
  • 5Il Jin Cho,Ji Yun Ahn,Suna Kim,Myung Sook Choi,Tae Youl Ha.Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters[J]. Biochemical and Biophysical Research Communications . 2007 (1)
  • 6Marie Lagouge,Carmen Argmann,Zachary Gerhart-Hines,Hamid Meziane,Carles Lerin,Frederic Daussin,Nadia Messadeq,Jill Milne,Philip Lambert,Peter Elliott,Bernard Geny,Markku Laakso,Pere Puigserver,Johan Auwerx.Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α[J]. Cell . 2006 (6)
  • 7Wataru Tomeno,Masato Yoneda,Kento Imajo,Yuji Ogawa,Takaomi Kessoku,Satoru Saito,Yuichiro Eguchi,Atsushi Nakajima.Emerging drugs for non-alcoholic steatohepatitis[J]. Expert Opinion on Emerging Drugs . 2013 (3)
  • 8Goiuri Alberdi,Víctor M. Rodríguez,M. Teresa Macarulla,Jonatan Miranda,Itziar Churruca,María P. Portillo.Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet[J]. Nutrition . 2013
  • 9Karina B. Cullberg,Jens Olholm,S?ren K. Paulsen,Casper B. Foldager,Martin Lind,Bj?rn Richelsen,Steen B. Pedersen.Resveratrol has inhibitory effects on the hypoxia-induced inflammation and angiogenesis in human adipose tissue in vitro[J]. European Journal of Pharmaceutical Sciences . 2013 (2)
  • 10Juliana G. Franco,Patrícia C. Lisboa,Natália S. Lima,Taline A.S. Amaral,Nayara Peixoto-Silva,Angela C. Resende,Elaine Oliveira,Magna C.F. Passos,Egberto G. Moura.Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning[J]. The Journal of Nutritional Biochemistry . 2013 (6)

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部